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Long interspersed element type 1 (LINE-1, L1) is a mobile genetic element comprising
about 17% of the human genome, encoding a newly identified ORF0 with unknown
function, ORF1p with RNA-binding activity and ORF2p with endonuclease and reverse
transcriptase activities required for L1 retrotransposition. L1 utilizes an endonuclease
(EN) to insert L1 cDNA into target DNA, which induces DNA double-strand breaks
(DSBs). The ataxia-telangiectasia mutated (ATM) is activated by DSBs and subsequently
the ATM-signaling pathway plays a role in regulating L1 retrotransposition. In addition,
the host DNA repair machinery such as non-homologous end-joining (NHEJ) repair
pathway is also involved in L1 retrotransposition. On the other hand, L1 is an
insertional mutagenic agent, which contributes to genetic change, genomic instability,
and tumorigenesis. Indeed, high-throughput sequencing-based approaches identified
numerous tumor-specific somatic L1 insertions in variety of cancers, such as colon
cancer, breast cancer, and hepatocellular carcinoma (HCC). In fact, L1 retrotransposition
seems to be a potential factor to reduce the tumor suppressive property in HCC.
Furthermore, recent study demonstrated that a specific viral-human chimeric transcript,
HBx-L1, contributes to hepatitis B virus (HBV)-associated HCC. In contrast, host cells
have evolved several defense mechanisms protecting cells against retrotransposition
including epigenetic regulation through DNA methylation and host defense factors, such
as APOBEC3, MOV10, and SAMHD1, which restrict L1 mobility as a guardian of the
human genome. In this review, I focus on somatic L1 insertions into the human genome
in cancers and host defense mechanisms against deleterious L1 insertions.
Keywords: LINE-1, retrotransposition, DNA double-strand breaks (DSBs), DNA repair, tumor suppressor, HBV,
epigenetic regulation, somatic insertion
INTRODUCTION
Long interspersed element type 1 (LINE-1, L1) is an active and autonomous non-long terminal
repeat (LTR) retrotransposon composing about 17% of the human genome and L1 is an
essential evolutionary force (DeBerardinis et al., 1998; Ostertag and Kazazian, 2001; Cordaux
and Batzer, 2009; Hancks and Kazazian, 2012). However, only 100 copies out of ∼500,000
copies still remain active (Brouha et al., 2003; Mills et al., 2007; Beck et al., 2010). The
remaining L1s are 5′ truncated and defective. Furthermore, L1 provides the trans-acting functions
required for the retrotransposition of non-autonomous retrotransposons such as short interspersed
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element (SINE), which includes Alu repeats in humans, SINE-
VNTR-Alu (SVA), and processed pseudogenes (Esnault et al.,
2000; Dewannieux et al., 2003; Hancks et al., 2011).
L1 encodes three open reading frames, a newly identified
ORF0 with unknown function, ORF1p with RNA-binding and
nucleic acid chaperon activities, and ORF2p with AP-like
endonuclease (EN) and reverse transcriptase (RT) activities
required for L1 retrotransposition (Mathias et al., 1991; Martin
and Bushman, 2001; Ostertag and Kazazian, 2001; Hancks
and Kazazian, 2012; Denli et al., 2015). ORF0 is the primate-
specific ORF in the anti-sense 5′ untranslated region (UTR)
of L1 (Denli et al., 2015). ORF0 predominantly localizes in
nuclear PML-adjacent foci and enhances L1 mobility. ORF1p
and ORF2p preferentially assemble with L1 RNA and form
a ribonucleoprotein (RNP) in the cytoplasmic foci (Goodier
et al., 2007; Doucet et al., 2010). Although retroviruses and
LTR-retrotransposons utilize a long terminal repeat (LTR)
to synthesize full-length transcripts, L1 instead utilizes an
internal promoter in the 5′UTR of L1 (Swergold, 1990). Several
transcription factors including SOX11 (Tchenio et al., 2000), YY1
(Becker et al., 1993; Athanikar et al., 2004), RUNX3 (Yang et al.,
2003), and p53 (Harris et al., 2009) positively regulate the L1
transcription. On the other hand, SOX2 (Muotri et al., 2005) and
SRY (Tchenio et al., 2000) as well as several epigenetic factors
negatively regulate the L1 transcription (Table 1).
L1 integrates into the genome by target-primed reverse
transcription (TPRT) (Luan et al., 1993) after the L1-RNP
complex enters the nucleus. During TPRT, the L1 EN creates
a nicked DNA that serves as a primer for reverse transcription
of L1 RNA, leading to integration of L1 cDNA into the human
genome (Feng et al., 1996). A typical L1 EN cleavage site is 5′-
TTTT/AA-3′ (Feng et al., 1996; Cost and Boeke, 1998). Thus,
L1 insertion generates DNA double-strand breaks (DSBs) as well
as L1 structural hallmarks such as frequent 5′ truncations, 3′
poly(A) tails and variable length target site duplications (TSDs)
in the target DNA. L1 can alter the mammalian genome in many
ways upon retrotransposition, since the insertion of L1 into the
human genome may cause genomic instability, genetic disorders,
and cancers through insertional mutagenesis (Kazazian et al.,
1988; Morse et al., 1988; Miki et al., 1992; Narita et al., 1993;
Holmes et al., 1994; Gilbert et al., 2002; Morrish et al., 2002;
Symer et al., 2002; Belancio et al., 2008; Beck et al., 2011;
Hancks and Kazazian, 2012; Bundo et al., 2014; Kines et al.,
2014; Figure 1). So far, >100 disease-causing retrotransposon
insertions have been identified in humans [26 L1, 61 Alu, 12 SVA,
4 poly(A)] (Figure 1).
L1-MEDIATED DSBs INDUCTION AND DNA
REPAIR MACHINERY
L1 is known to induce DSBs in target DNA by L1 EN
activity (Gasior et al., 2006). The ataxia-telangiectasia mutated
(ATM) is activated by DSBs and subsequently phosphorylates
downstream substrates including p53, Chk2, BRCA1 and the
MRE11-Rad50-NBS1 (MRN) complex, resulting in the activation
of DNA damage checkpoint and cell cycle arrest (Harper
TABLE 1 | Host factors regulating the L1 transcription.
Host factors Functions References
POSITIVE FACTOR
RNA polymerase II RNA polymerase Swergold, 1990; Beck
et al., 2011
SOX11 Transcription factor Tchenio et al., 2000
YY1 Transcription factor Becker et al., 1993;
Athanikar et al., 2004
RUNX3 Transcription factor Yang et al., 2003




Yu et al., 2001; Muotri
et al., 2010
KAP1/TRIM28 Cofactor of KRAB zinc
finger protein
Rowe et al., 2010;
Castro-Diaz et al., 2014
SETDB1/ESET Histone
methyltransferase
Matsui et al., 2010
DNMT1, DNMT3a,
DNMT3b
DNA methyltransferase Liang et al., 2002
ZNF93 KRAB zinc finger
protein
Jacobs et al., 2014
PLZF Transcription factor Puszyk et al., 2013
SIRT6 Mono-ADP-ribosyl
transferase
Van Meter et al., 2014
SOX2 Transcription factor Muotri et al., 2005
SRY Transcription factor Tchenio et al., 2000
p53 Tumor suppressor Wylie et al., 2016
Rb Tumor suppressor Montoya-Durango
et al., 2009, 2016
HDAC1 Histone deacetylase Montoya-Durango
et al., 2009
HDAC2 Histone deacetylase Montoya-Durango
et al., 2009, 2016






and Elledge, 2007; Ciccia and Elledge, 2010; Shiloh, 2014).
Accordingly, L1 retrotransposition was increased in ATM-
deficient cells, indicating ATM signaling pathway modulates
L1 retrotransposition (Coufal et al., 2011). In contrast, the
E6 protein from β-human papillomavirus (β-HPV 5 and 8)
reduces ATM protein levels and attenuates L1 retrotransposition,
suggesting that ATM is needed for efficient L1 retrotransposition
(Wallace et al., 2013). Thus, the DNA damage response may
modulate L1 retrotransposition. Notably, L1 can integrate into
preformed DSBs generated independently of L1 EN, resulting
in retrotransposon-mediated DNA repair (Morrish et al., 2002).
Furthermore, host DNA repair machinery may also impact L1
retrotransposition. Gasior et al reported that DNA repair enzyme
ERCC1/XPF heterodimer limits L1 retrotransposition (Gasior
et al., 2008). Importantly, deficiencies of non-homologous end-
joining (NHEJ) repair pathway such as Ku70, Artemis, and
DNA ligase IV (LigIV) decrease retrotransposition frequencies of
human L1 in chicken DT40 cells, suggesting that the NHEJ repair
Frontiers in Chemistry | www.frontiersin.org 2 June 2016 | Volume 4 | Article 28
Ariumi LINE-1 and Host Defense Mechanisms
FIGURE 1 | Germline Alu insertion in the human genome causes hemophilia and somatic L1 insertion causes colon cancer. L1 insertions have also been
observed in Factor VIII and this causes hemophilia A. Disease causing L1 and Alu insertions are also found in genes that are X-linked inherited. >100 disease-causing
retrotransposon insertions have been identified in humans [26 L1, 61 Alu, 12 SVA, 4 poly(A)].
pathway is required for efficient L1 retrotransposition (Suzuki
et al., 2009).
L1 RETROTRANSPOSITION IN CANCERS
Somatic L1 insertions are seldom observed in normal tissues
except hippocampus (Baillie et al., 2011; Evrony et al., 2012;
Upton et al., 2015). Although most L1 retrotransposition was
thought to occur in the germline, somatic L1 insertions were
also found to occur in variety of tumors, including breast
cancer, colon cancer, hepatocellular carcinoma (HCC), and
lung cancer (Miki et al., 1992; Liu et al., 1997; Iskow et al.,
2010; Lee et al., 2012; Solyom et al., 2012; Shukla et al., 2013;
Carreira et al., 2014; Helman et al., 2014; Ewing et al., 2015;
Table 2). First, three L1 insertion candidates were reported
in human tumors (Morse et al., 1988; Miki et al., 1992;
Liu et al., 1997). However, two insertions described by Liu
et al. (1997) and Morse et al. (1988) lack all of the hallmark
features of a true somatic retrotransposition event, such as
L1 endonuclease cleavage site, the presence of L1 poly(A)
tail, target-site duplication (TSD), 5′ truncation and inversion,
and 3′ transduction (Holmes et al., 1994; Moran et al., 1999;
Goodier et al., 2000; Pickeral et al., 2000; Szak et al., 2002;
Table 2). These insertions may be derived from recombination
events, L1 EN-independent insertions (Morrish et al., 2002), or
other atypical integration mechanisms of L1 retrotransposition.
Indeed, an L1 insertion disrupts the adenomatous polyposis
coli (APC) gene in a colon cancer, indicating the disruption
of a tumor suppressor gene caused by somatic L1 insertion
(Miki et al., 1992). Accordingly, a recent study identified a
novel somatic insertion in the APC gene and a hot spot for L1
insertion on Chromosome 17, suggesting that the L1 insertion
initiates colorectal cancer (CRC) by mutating the APC gene
through the classic two-hit CRC pathway (Scott et al., 2016).
Furthermore, high-throughput sequencing-based approaches
identified numerous somatic tumor-specific insertions in cancers
(Miki et al., 1992; Liu et al., 1997; Iskow et al., 2010; Lee
et al., 2012; Solyom et al., 2012; Shukla et al., 2013; Carreira
et al., 2014; Helman et al., 2014; Tubio et al., 2014). Indeed,
Lee et al. identified the L1 insertions in cadherin-12 (CDH12),
roundabout, axon guidance receptor, homolog 2 (ROBO2),
NRXN3, FPR2, COL11A1, NEGR1, NTM, and CTNNA2 (Lee
et al., 2012). As well, Solyom et al. identified several tumor-
specific insertions in colorectal tumors including odd Oz/ten-
m homolog 3 (ODZ3), ROBO2, protein tyrosine phosphatase,
receptor type, M (PTPRM), pericentriolar material 1 (PCM1),
CDH11, and runt-related transcription factor 1 (RUNX1T1) of
colorectal cancers (Solyom et al., 2012). All insertions were
severely 5′ truncated. Interestingly, these genes are associated
with cell-adhesion functions and both groups could identify the
L1 insertions in the same ROBO2 genes, suggesting the potential
role of cell-adhesion genes in L1 insertion-mediated colorectal
tumorigenesis. In addition, Tubio et al. analyzed the somatic L1
retrotransposition activities in 290 cancers and noticed insertions
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TABLE 2 | L1 insertions in cancers.









Breast cancer + Myc (*) Morse et al., 1988





Solyom et al., 2012





Lee et al., 2012
+ 57 somatic L1
insertions CYLD, HDAC9
Ewing et al., 2015
Colonic adenoma + 29 somatic L1
insertions STX11, PANX1





Liu et al., 1997
Endometrial carcinoma + PTEN Helman et al., 2014
Esophageal
adenocarcinoma




Familial retinoblastoma + RB1 Rodríguez-Martín et al.,
2016
Gastric cancer + 23 somatic L1
insertions ELOVL4,
CNTNAP2, RIMS2
Ewing et al., 2015




+ MCC, ST18 Shukla et al., 2013
HBV integration in L1
(HBx-LINE1)
Lau et al., 2014
Head and neck
carcinoma
+ Helman et al., 2014
Lung cancer + 9 somatic L1 insertions Iskow et al., 2010
Medulloblastoma − Iskow et al., 2010
Multiple Myeloma − Lee et al., 2012
Neurofibromatosis type
1 (NF1)
+ NF1 3 L1 insertions Wimmer et al., 2011
Ovarian tumors + 13 somatic L1
insertions
Lee et al., 2012
Pancreatic cancer + 24 somatic L1
insertions SOX6, APAF1,
GDNF
Ewing et al., 2015
Pancreatic ductal + 465 somatic L1
insertions
Rodic´ et al., 2015
adenocarcinoma
(PDAC)
In 20 PDAC cases
Prostate tumors + Lee et al., 2012
*Lack of the hallmark features of a true somatic retrotransposition event (Morse et al.,
1988; Liu et al., 1997).
occurring during cancer development. 53% of the patients have
at least one somatic L1 retrotransposition event, of which 24%
were 3′ transductions, most frequently colorectal cancers (93%)
and lung cancers (75%), suggesting that 3′ transduction are
potentially mutagenic. Somatic L1 retrotranspositions tend to
insert in intergenic or heterochromatin regions of the cancer
genome (Tubio et al., 2014). Furthermore, somatic L1 insertions
participate in the dynamics of many tumor genomes and lead
to driver mutations. Surprisingly, L1 insertion was reported in
colonic adenoma, a known cancer precursor, suggesting that
widespread somatic L1 retrotransposition occurs early during
development of gastrointestinal (GI) tumors, probably before
dysplastic growth (Ewing et al., 2015). Similarly, a recent study
demonstrated that L1 retrotransposition is active in esophageal
adenocarcinoma and its precursor, Barrett’s esophagus (BE),
indicating that somatic L1 insertions occur early in BE and
esophageal adenocarcinoma. Notably, two L1 insertions were
detected in normal esophagus, indicating that some L1 insertions
may occur in normal squamous epithelium cells (Doucet-O’Hare
et al., 2015). In this regard, most of the new somatic insertions are
truncated, and would not mobilize again. So mutations arising
from insertions in the normal precursor esophageal or benign BE
would be contributing to tumorigenesis. Otherwise, only a rare
full-length somatic insertion has the potential to contribute to
mutation during the various stages of transition to tumorigenesis.
In addition, L1 insertions in pancreatic ductal adenocarcinoma
(PDAC) were reported with discordant rate of retrotransposition
between primary and metastatic sites, suggesting that L1
insertions in gastrointestinal neoplasms occur discontinuously.
Thus, somatic L1 insertions contribute to genetic and phenotypic
heterogeneity in PDAC (Rodic´ et al., 2015). Interestingly, somatic
insertions were identified in epithelial tumors but not in blood
or brain cancers (Lee et al., 2012). However, we raise awareness
regarding the following limitations of this study. For example,
the sample size was small and the normal tissue was not
from the same patient. In addition, in this study they only
examined multiple myeloma and did not look at the entire
spectrum of blood based cancers. In this regard, ten-eleven-
translocation (TET) 2, a DNA demethylation-related protein,
is frequently mutated in myeloid and lymphoid tumors (Ko
et al., 2015). The TET family that oxidizes 5-methylcytosine
(5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine
(5fC), and 5-carboxylcytosine (5caC) in DNA, leads to the DNA
demethylation. Since DNA methylation has a pivotal regulatory
role in L1 silencing, TET2 may impact L1 mobility. Therefore,
L1 insertions may be suppressed in such hematological cancers.
Intriguingly, several somatic insertions occur in genes that are
commonly mutated in cancers such as tumor suppressor gene.
These insertions disrupt the expression of target genes, and are
biased toward regions of cancer-specific DNA hypomethylation
(Lee et al., 2012). Indeed, recent studies identified somatic L1
insertion in tumor suppressor genes, such as APC and PTEN
(Miki et al., 1992; Helman et al., 2014). As well, the first case
of familial retinoblastoma (Rb) caused by a de novo insertion
of a full-length L1 into intron 14 of the Rb gene, resulting in
the aberrant and non-canonical mRNA splicing of the Rb gene,
was reported (Rodríguez-Martín et al., 2016). Furthermore, 18
retrotransposon insertions [14 Alu, 3 L1, and 1 poly(A)] were
identified in neurofibromatosis type 1 (NF1) gene (Wimmer
et al., 2011).
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Although still debated, cell division seems to be required for
efficient L1 retrotransposition (Shi et al., 2007; Xie et al., 2013).
In fact, retrotransposition was strongly inhibited in the cells
arrested in the G1, S, G2, or M phase of cell cycle. The reduction
in L1 transcript abundance limits retrotransposition in non-
dividing cells, suggesting that inhibition of retrotransposition in
non-dividing cells protects somatic cells from accumulation of
deleterious mutations caused by L1 insertions (Shi et al., 2007).
In contrast, there is an opposite report that L1 retrotransposition
was detected in non-dividing and primary human somatic cells
using adenovirus-L1 hybrid vector, even though they detected
L1 retrotransposition in G1/S- but not in G0-arrested cells (Kubo
et al., 2006). In addition, retrotransposition was also inhibited
during cellular senescence in primary human fibroblasts. So far,
several biomarkers of cellular senescence have been identified
such as senescence-associated β-galactosidase (SA-β-Gal),
p53/p21, p16INK4a, senescence-associated heterochromatin foci
(SAHF), senescence-associated secretory phenotype (SASP),
autophagy, telomere-induced foci/DNA damage response
(DDR), and cell cycle arrest (Kuilman et al., 2010) and the
reduction in L1 retrotransposition may be a biomarker of cellular
senescence. Thus, cell cycle may affect L1 retrotransposition.
L1 protein expression is a common feature of many types of
high-grade malignant tumor, yet is rarely detected in early stage
of tumorigenesis (Rodic´ et al., 2014). L1 promoter is normally
silenced by methylation in normal somatic cells (Woodcock
et al., 1997; Schulz et al., 2006). In contrast, L1 promoter is
hypomethylated (Baba et al., 2014), and expression of L1 is
elevated in many tumors. In fact, L1 expression was detected
in human breast carcinomas and testicular cancers (Bratthauer
and Fanning, 1992; Bratthauer et al., 1994; Nangia-Makker et al.,
1998). L1 ORF1p protein is detected in a variety of tumor
cells including breast cancer, colon cancer, pancreatic ductal
adenocarcinoma, and HCC but not in normal somatic cells
(Bratthauer et al., 1994; Asch et al., 1996; Rodic´ et al., 2014). Thus,
L1 ORF1p expression seems to be a hallmark of many human
cancers as a highly specific tumor marker.
In addition to expression of L1, a hallmark of tumor cells
is an activated telomere maintenance mechanism that allows
prolonged survival of the malignant tumor cells. In more than
80% of tumors, telomeres are typically maintained by telomerase.
Notably, the reduced length of telomeres was reported in the
L1 knockdown cells, indicating that L1 is involved in telomere
maintenance in telomerase positive tumor cells (Aschacher et al.,
2016). Accordingly, L1 involves in a transcriptional regulation of
hTERT and upregulation of its transcription factors c-Myc and
KLF-4 (Aschacher et al., 2016). Thus, L1 may contribute to the
development of cancers. However, these studies were not done
in alternative lengthening of telomeres (ALT)-positive tumors or
telomerase negative tumors. Consequently, it is uncertain if L1 is
directly contributing to telomere maintenance or if the reduction
in telomere length is contributed to the reduction in telomerase
levels. Indeed, the stoichiometry of telomerase is important for
maintaining telomere length (Armanios et al., 2005; Goldman
et al., 2005).
Chronic infection with hepatitis B virus (HBV) is a major
risk for the development of HCC. HBV integration into the
human genome was found in most HBV-related HCC and
it has been implicated in the development of HCC. An
initial study proposed that HBV integration occurs randomly
without preferred integration site (Matsubara and Tokino,
1990). However, high-throughput sequencing-based approaches
identified recurrent integration sites in HCC (Ding et al., 2012).
HBV integration favored chromosome 17 and preferentially
integrated into human transcript units. At least, telomerase
reverse transcriptase (TERT) and fibronectin 1 (FN1) genes were
identified as the recurrent HBV integration sites. Furthermore,
seven integrations were found in the repeat regions including
L1, LTR/ERV1, and SINE/Alu (Ding et al., 2012). Similarly, a
recent transcriptome sequencing study of HBV-positive HCC
cell lines discovered that HBV integrates into L1 (Lau et al.,
2014). Insertion of the gene encoding hepatitis B virus x (HBx)
into L1 on chromosome 8p11 produces an oncogenic HBx-
LINE1 chimeric RNA transcript (Lau et al., 2014; Figure 2).
The HBx-LINE1 RNA transcript was detected in 23.3% of
HCC, suggesting that HBx-LINE1 is selected for in HCC
oncogenesis. The long non-coding RNA (lncRNA)-like HBx-
LINE1 transcript confers cancer-promoting properties through
activation of Wnt/β-catenin signaling pathway (Lau et al., 2014).
Furthermore, endogenous L1-mediated retrotransposition
was identified in the germline and somatic cells of HCC patients
(Shukla et al., 2013). The germline L1 insertion in the tumor
FIGURE 2 | HBV integration into LINE1 in HCC. Schematic representation
of the HBx-LINE1 fusion RNA transcript and potential role of oncogenic
HBx-LINE1 fusion RNA transcript in HCC.
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suppressor mutated in colorectal cancers (MCC) was detected
in 21.1% of HCC, resulting in the aberrant expression of MCC.
Moreover, suppression of tumorigenicity 18 (ST18) was activated
by a tumor-specific somatic L1 insertion (Shukla et al., 2013).
Thus, L1-mediated retrotransposition seems to be a potential
etiological factor in HCC.
GUARDIAN OF THE HUMAN GENOME:
HOST DEFENSE MECHANISMS AGAINST
L1 RETROTRANSPOSITION
Since insertion of L1 into the human genome may cause
human genetic disorders and cancer, retrotransposition must
be silenced under normal conditions. To restrict deleterious
retrotransposition, host cells have evolved several defense
mechanisms protecting cells against retrotransposition including
epigenetic regulation through DNA methylation (Burden et al.,
2005; Trono, 2015), RNA silencing by RNA interference (Soifer
et al., 2005; Yang and Kazazian, 2006), PIWI-interacting RNA
(piRNA)-PIWI system (Aravin et al., 2007a,b; Kuramochi-
Miyagawa et al., 2008; De Fazio et al., 2011; Marchetto et al.,
2013), microRNA (Hamdorf et al., 2015), and host restriction
factors, such as apolipoprotein B mRNA editing enzyme catalytic
polypeptide-like 3 (APOBEC3), Moloney leukemia virus 10
(MOV10), and SAM domain and HD domain containing protein
1 (SAMHD1) (Table 3).
DNA methylation within the 5′UTR promoter of L1 is
essential for maintaining transcriptional inactivation and for
inhibiting L1 retrotransposition (Woodcock et al., 1997; Liang
et al., 2002; Burden et al., 2005). L1 is highly active during early
embryogenesis, while L1 is silenced early in development through
epigenetic mechanisms (Table 1). Indeed, methylation of the L1
promoter is maintained by DNA metyltransferases (DNMTs),
including DNMT1, DNMT3a, and DNMT3b (Liang et al., 2002).
L1 retrotransposition is negatively regulated by methyl-CpG-
binding protein 2 (MeCP2)-mediated DNA methylation (Yu
et al., 2001; Muotri et al., 2010). In addition, nucleosomal
and remodeling deacetylase (NuRD) multiprotein complex
specifically enriches the L1 promoter. Rb and E2F recruit
to the L1 promoter along with histone deacetylase (HDAC),
including HDAC1 and HDAC2 (Montoya-Durango et al.,
2009, 2016). Furthermore, KRAB-associated protein1 (KAP1,
also known as TRIM28) mediates transcriptional silencing of
endogenous retroelements (EREs) including L1, Alu, SVA, and
human endogenous retrovirus-K (HERV-K) as well as exogenous
retrovirus mouse leukemia virus (MLV) in embryonic stem (ES)
cells (Wolf and Goff, 2007, 2009; Matsui et al., 2010; Rowe
et al., 2010; Castro-Diaz et al., 2014; Turelli et al., 2014; Trono,
2015). Krüppel-associated box (KRAB)-containing zinc-finger
protein (KRAB-ZFP/ZNF), a large family of tetrapod-restricted
transcription factors, and a cofactor KAP1 serve as a scaffold
for a heterochromatin complex comprising the SETDB1 (also
known as ESET) histone methyltransferase, histone deacetylase,
nucleosome remodeling, and DNMT activities (Trono, 2015;
Figure 3). Furthermore, the protein deacylase and mono-ADP
ribosyltransferase Sirtuin 6 (SIRT6) represses L1 mobility by
TABLE 3 | Host defense factors against L1.
Host factors Functions References
APOBEC3A ISG, cytidine deaminase Bogerd et al., 2006; Chen
et al., 2006; Muckenfuss et al.,
2006; Kinomoto et al., 2007;
Niewiadomska et al., 2007
APOBEC3B Cytidine deaminase Bogerd et al., 2006;
Muckenfuss et al., 2006;
Stenglein and Harris, 2006;
Kinomoto et al., 2007
APOBEC3F ISG, cytidine deaminase
anti-viral protein
Muckenfuss et al., 2006;
Stenglein and Harris, 2006;
Kinomoto et al., 2007;
Niewiadomska et al., 2007
APOBEC3G ISG, cytidine deaminase
anti-viral protein
Kinomoto et al., 2007;
Niewiadomska et al., 2007
MOV10 ISG, RNA helicase
anti-HIV protein
Arjan-Odedra et al., 2012;
Goodier et al., 2012, 2013; Li
et al., 2013
BST-2 ISG, anti-HIV protein Goodier et al., 2015
ISG20 ISG, anti-viral protein Goodier et al., 2015
MAVS ISG, innate immunity Goodier et al., 2015
Mx2 ISG, anti-viral protein Goodier et al., 2015
RNase L ISG, anti-viral protein Zhang et al., 2014
SAMHD1 ISG, anti-HIV protein Zhao et al., 2013; Hu et al.,
2015
TREX1 ISG, DNA exonuclease Stetson et al., 2008
ZAP/PARP13 ISG, poly(ADP-ribose)
polymerase
Goodier et al., 2015; Moldovan
and Moran, 2015
IFN1 Induction of ISGs,
anti-viral protein
Yu et al., 2015
MeCP2 Methyl-CpG-binding
protein
Yu et al., 2001; Muotri et al.,
2010
KAP1/TRIM28 Cofactor of KRAB zinc
finger protein




Matsui et al., 2010
ZNF93 KRAB zinc finger protein Jacobs et al., 2014
PLZF Transcription factor Puszyk et al., 2013
SIRT6 Mono-ADP-ribosyl
transferase
Van Meter et al., 2014
SOX2 Transcription factor Muotri et al., 2005
SRY Transcription factor Tchenio et al., 2000
p53 Tumor suppressor Wylie et al., 2016
Rb Tumor suppressor Montoya-Durango et al., 2009,
2016
ATM DNA damage sensor,
kinase
Coufal et al., 2011
ERCC1/XPF DNA repair Gasior et al., 2008
miR-128 microRNA Hamdorf et al., 2015
piRNA-PIWI piRNA De Fazio et al., 2011;
Marchetto et al., 2013
ribosylating KAP1 (Van Meter et al., 2014). SIRT6 binds to
the 5′UTR of L1 and ribosylates KAP1, resulting in facilitation
of KAP1 interaction with the heterochromatin factor HP1α,
thereby contributing to the packaging of L1 into transcriptionally
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FIGURE 3 | The KRAB/KAP1 system controls the transcriptional
activity of L1 in ES cells. KRAB/KAP1 serves as a scaffold for a
heterochromatin complex comprising the SETDB1 and DNMT.
repressive heterochromatin. Moreover, promyelocytic leukemia
zinc finger (PLZF) protein, a member of the POK (POZ and
Kruppel zinc finger) family of transcription factors that acts as
an epigenetic regulator of stem cell maintenance in germ cells
and haematopoietic stem cells, represses L1 retrotransposition in
germ and progenitor cells (Puszyk et al., 2013). PLZF-mediated
DNA methylation induces silencing of the L1 gene, resulting
in inhibition of L1 retrotransposition. Species-specific KZNFs
might recruit KAP1 to species-specific retrotransposon classes
that recently invaded the host genome. In this regard, Jacobs
et al. recently reported that two primate-specific ZNF91 and
ZNF93 repress SVA and L1 retrotransposons, respectively (Jacobs
et al., 2014). ZNF93 evolved earlier to repress the primate L1
lineage until ∼12.5 million years ago when the L1PA3 subfamily
escaped ZNF93-mediated restriction through the removal of
the ZNF93-binding site, suggesting an evolutionary arms race
between KRAB-ZNFs and retrotransposons (Jacobs et al., 2014).
Post-translational modification and subcellular localization
of L1 protein seem to be important for modulation of L1
mobility. In fact, phosphorylation of ORF1p is required for
L1 retrotransposition (Cook et al., 2015). L1 ORF1p contains
four conserved proline-directed protein kinase (PDPKs) target
sites. PDPK mutations in ORF1p could inactivate L1 mobility
(Cook et al., 2015). The PDPK family includes mitogen-activated
protein kinases (MAPKs) and cyclin-dependent kinases (CDKs).
Although nuclear localization of L1 ORF1p and ORF2p is
essential for L1 retrotransposition, L1 ORF1p predominantly
localizes in punctate cytoplasmic foci in most of cases (Goodier
et al., 2007; Harris et al., 2010; Chen et al., 2012). However, in
several breast cancers, LI ORF1p and ORF2p were also detected
in the nucleus (Harris et al., 2010; Chen et al., 2012). Indeed, the
expression of L1 is elevated in breast cancers.
Recently, APOBEC3 family of cytidine deaminases, MOV10,
and SAMHD1 have been identified as restriction factors for
human immunodeficiency virus type 1 (HIV-1) (Sheehy et al.,
2002; Harris et al., 2003; Mangeat et al., 2003; Zhang et al.,
2003; Burdick et al., 2010; Furtak et al., 2010; Wang et al.,
2010; Hrecka et al., 2011; Laguette et al., 2011). APOBEC3A,
APOBEC3B, and APOBEC3F but not APOBEC3G inhibit L1
retrotransposition by a DNA deaminase-independent manner,
indicating a novel anti-L1 retrotransposition mechanism (Turelli
et al., 2004; Bogerd et al., 2006; Chen et al., 2006; Muckenfuss
et al., 2006; Stenglein and Harris, 2006; Hulme et al., 2007;
Kinomoto et al., 2007; Niewiadomska et al., 2007; Schumann,
2007; Arias et al., 2012). In contrast, Kinomoto et al. and
Niewiadomska et al. reported that APOBEC3G could inhibit
L1 retrotransposition by a DNA deamination-independent
manner (Kinomoto et al., 2007; Niewiadomska et al., 2007).
Furthermore, APOBEC3G inhibits Alu retrotransposition by a
DNA deaminase-independent manner (Chiu et al., 2006; Hulme
et al., 2007; Bulliard et al., 2009). MOV10 RNA helicase also
inhibits L1 and Alu retrotransposition (Arjan-Odedra et al.,
2012; Goodier et al., 2012, 2013; Li et al., 2013). Similarly,
SAMHD1 inhibits LINE-1 and Alu/SVA retrotransposition
(Zhao et al., 2013). SAMHD1 inhibits L1 retrotransposition
through promoting the sequestration of L1 RNP within stress
granules (Hu et al., 2015). Similarly, the zinc-finger antiviral
protein (ZAP) also known as PARP13, a member of poly(ADP-
ribose) polymerase (PARP) family, inhibits the retrotransposition
of L1, Alu, and intracisternal A particle (IAP) retrotransposons
(Goodier et al., 2015; Moldovan andMoran, 2015). ZAP interacts
with L1 RNA and L1ORF1p and co-localizes with stress granules.
Type I interferons (IFN 1) including IFNα and IFNβ have been
involved in innate immunity against viruses. In this regard, a
recent study reported that L1 induces IFN1 and IFN1, in turn,
inhibits L1 retrotransposition, suggesting that IFN1 controls
propagation of L1 as well as maintenance of genomic integrity
(Yu et al., 2015). Accordingly, several interferon-stimulated
genes (ISGs), including APOBEC3, MOV10, BST-2, ISG20,
MAVS, MX2, RNase L, SAMHD1, TREX1, and ZAP restrict L1
retrotransposition, indicating that ISGs are key players of the
type I interferon anti-retroelement response (Turelli et al., 2004;
Bogerd et al., 2006; Chen et al., 2006; Muckenfuss et al., 2006;
Stenglein and Harris, 2006; Hulme et al., 2007; Kinomoto et al.,
2007; Niewiadomska et al., 2007; Schumann, 2007; Stetson et al.,
2008; Arias et al., 2012; Zhao et al., 2013; Zhang et al., 2014;
Goodier et al., 2015; Hu et al., 2015; Table 3).
Small RNAs have been implicated in the regulation of L1
mobility. Piwi proteins and Piwi-interacting RNAs (piRNA)
silence L1 during genome reprogramming in the embryonic
male germ line (De Fazio et al., 2011; Marchetto et al., 2013).
Notably, Hamdorf et al. uncovered a new mechanism in which
microRNAs restrict L1mobilization and L1-associatedmutations
in cancer cells, cancer-initiating cells and iPS cells (Hamdorf
et al., 2015). Indeed, miR-128 represses L1 retrotransposition
by binding directly to L1 RNA, suggesting a new function of
microRNAs in mediating genomic stability by suppressing the
mobility of endogenous retrotransposons.
Tumor suppressor p53 mutations occur in most of human
cancers, however, precisely how p53 functions to mediate
tumor suppression is not well understood. In this regard,
p53 was reported to restrict L1 mobility and suggested that
p53 restricts oncogenesis in part by restricting transposon
mobility (Wylie et al., 2016). Although normal human p53
suppressed transposons, mutant p53 from cancer patients could
not. In contrast, L1 activity was elevated in p53 negative
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human cancers. Thus, ancestral function of p53 may be
associated with transposon control as a guardian of human
genome.
CONCLUSION
L1 has successfully propagated and composed 17% of the
human genome, resulting in evolutionary force. Activation
of the normally silent L1 is associated with a high level of
cancer-associated DNA damage and genomic instability. Indeed,
L1 insertions into the human genome may cause cancers
through insertional mutagenesis. In fact, recent high-throughput
sequencing-based approaches could identify numerous somatic
tumor-specific L1 insertions in a variety of cancers (Iskow
et al., 2010; Lee et al., 2012; Solyom et al., 2012; Shukla et al.,
2013; Helman et al., 2014), however there is no sufficient
evidence. Therefore, it should clarify the role of L1-mediated
retrotransposition in human cancers. Indeed, the implication of
L1 insertion events as either passenger or driver mutations with
a causative role in tumorigenesis still remains to be clarified
(Rodic´ and Burns, 2013). Intriguingly, somatic insertions were
only identified in epithelial tumors (Lee et al., 2012). Accordingly,
epithelial cells can be transformed to cancer stem cells (Wang
et al., 2013) and metastasis is more prevalent in epithelial tumors
(Gotzmann et al., 2004). Thus, epithelial cells seem to be plastic
(Carreira et al., 2014). Cancer stem cells are defined as rare cells
with indefinite potential for self-renewal that drive tumorigenesis
(Reya et al., 2001). However, it remains to be clarified the
role of L1 mobility in cancer stem cells. Recent studies focus
on the relationship among L1 mobility, reprogramming, and
differentiation. Indeed, reprogramming somatic cells into iPS
cells activates L1 mobility (Wissing et al., 2012; Friedli et al.,
2014; Klawitter et al., 2016). On the other hand, L1 mobility
is enhanced in tumor cells. In this regard, the elevation of L1
protein or RNA expression levels may be useful as a diagnostic
hallmark of many human cancers and as a tumor specific marker,
metastasis, and prognosis. Furthermore, recent advances in single
cell analysis will be useful for comparison of the L1 mobility and
the integration site of L1 at a single cell level in human cancers.
Finally, tumor suppressor proteins may be associated with
transposon control to restrict deleterious retrotransposition as
a guardian of the human genome. Wild-type p53 suppresses
transposon mobility in normal cells, while mutant p53 in cancer
cells could not, resulting in the activation of L1 mobility in
cancer cells (Wylie et al., 2016). Furthermore, recent studies
identified somatic L1 insertion in tumor suppressor genes, such
as APC, PTEN, NF1, and Rb (Miki et al., 1992; Wimmer et al.,
2011; Helman et al., 2014; Rodríguez-Martín et al., 2016). Thus,
L1 insertions in the tumor suppressor genes may disrupt their
functions and be associated with tumorigenesis. Altogether, host
cells have evolved several defense mechanisms protecting cells
against retrotransposition.
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